Last reviewed · How we verify

MK-4280A — Competitive Intelligence Brief

MK-4280A (MK-4280A) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CCR4 antagonist. Area: Oncology.

phase 3 CCR4 antagonist CCR4 (C-C chemokine receptor type 4) Oncology Biologic Live · refreshed every 30 min

Target snapshot

MK-4280A (MK-4280A) — Merck Sharp & Dohme LLC. MK-4280A is a selective antagonist of the chemokine receptor CCR4 that reduces the recruitment and activation of regulatory T cells and other immune cells to the tumor microenvironment.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
MK-4280A TARGET MK-4280A Merck Sharp & Dohme LLC phase 3 CCR4 antagonist CCR4 (C-C chemokine receptor type 4)
MK0831 MK0831 Merck Sharp & Dohme LLC phase 3 CCR4 antagonist CCR4
MK-4280 MK-4280 Merck Sharp & Dohme LLC phase 3 CCR4 antagonist CCR4 (C-C chemokine receptor type 4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CCR4 antagonist class)

  1. Merck Sharp & Dohme LLC · 3 drugs in this class
  2. Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MK-4280A — Competitive Intelligence Brief. https://druglandscape.com/ci/mk-4280a. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: